Marco Mielcarek, M.D.

Marco Mielcarek M.D.
faculty member

Marco Mielcarek, M.D.

Member
Clinical Research Division, Fred Hutch

Medical Director, Adult Blood and Marrow Transplantation
Fred Hutch / Seattle Cancer Care Alliance

Fax: 206.667.6124
Mailstop: D1-100

Dr. Marco Mielcarek is the medical director of the Adult Blood and Marrow Transplant Program at Seattle Cancer Care Alliance and Fred Hutch. His research focuses on graft-vs.-host disease, or GVHD, a potentially life-threatening complication in which newly transplanted cells attack the patient’s body. Dr. Mielcarek and his research colleagues are testing in clinical trials how to better prevent GVHD and how to effectively treat it without causing unwanted toxicity. He and his colleagues have shown that carefully timed infusions of high doses of cyclophosphamide, a common chemotherapy drug, can safely and effectively prevent GVHD after growth factor-mobilized blood stem transplantation.

Other Appointments & Affiliations

Professor
University of Washington School of Medicine

Education

M.D., Freie Universität Berlin, School of Medicine, Germany, 1986

Ph.D., Freie Universität Berlin, School of Medicine, 1987

Internal Medicine Residency, Freie Universität Berlin, 1987-1993

Internal Medicine Residency, University of Washington, 1998-2000

Medical Oncology Fellowship, University of Washington, 2000-2003

Research Interests

Preventing and more effectively treating graft-versus-host disease (GVHD) after allogeneic stem cell transplantation.

Find A Clinical Trial

For the Media

The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.

Email media@fredhutch.org or call 206.667.2210